Overrepresentation of the V kappa IV subgroup in light chain deposition disease.
The variability subgroup of human monoclonal kappa chains purified from urine in 3 consecutive patients with myeloma associated light chain deposition disease was determined from amino acid sequences of their first framework regions (FR1). N-glycosylation was searched for by N-glycosidase F treatment. These data together with our previously published results, indicate the pathogenic potential of the rare V kappa IV subgroup and confirm the absence of detectable serum and urine free monoclonal light chains when they are N-glycosylated.
Denoroy
L
L
Service Central d'Analyses, CNRS, Vernaison, France.
Déret
S
S
Aucouturier
P
P
D000595:Amino Acid Sequence; D001536:Bence Jones Protein / Q000235:genetics; D004591:Electrophoresis, Polyacrylamide Gel; D006031:Glycosylation; D006801:Humans; D007070:Immunoglobulin A / Q000302:isolation & purification*; D007145:Immunoglobulin kappa-Chains / Q000302:isolation & purification*; D008969:Molecular Sequence Data; D009101:Multiple Myeloma / Q000276:immunology*; D010265:Paraproteinemias / Q000276:immunology*
D007070:Immunoglobulin A; D007145:Immunoglobulin kappa-Chains; D001536:Bence Jones Protein